Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
11/10/2011
Trade Name:
HEMACORD
Generic or Proper Name (*):
hematopoietic progenitor cells, cord blood*
Indications Studied:
For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment
Therapeutic Category:
Somatic Cell
Ages Studied:
2 months - 72 years
Study #:
3
Study Type:
Efficacy/Safety
Study Design:
Retrospective
No Patients:
155
No Centers:
Multi
No Countries:
International
BPCA(B), PREA(P):
P
Asian:
0
Black:
0
Other:
0
White:
0
Unknown:
0
Native Hawaiian or Pacific Islander:
0
American Indian/Alaska Native:
0
Hispanic/Latino:
0
Non-Hispanic/Non Latino:
0
Countries:
NA
-
-